Alpha Cognition Files 8-K

Ticker: ACOG · Form: 8-K · Filed: Jul 29, 2024 · CIK: 1655923

Alpha Cognition INC. 8-K Filing Summary
FieldDetail
CompanyAlpha Cognition INC. (ACOG)
Form Type8-K
Filed DateJul 29, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, financials

TL;DR

Alpha Cognition filed an 8-K, likely with financial updates. Check for details.

AI Summary

Alpha Cognition Inc. filed an 8-K on July 29, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Neurodyn Cognition Inc., is incorporated in British Columbia and has its principal executive offices in Vancouver. The filing does not contain specific financial figures or details about the nature of the disclosures.

Why It Matters

This filing indicates that Alpha Cognition Inc. is making a public disclosure and submitting financial exhibits, which could contain important updates for investors.

Risk Assessment

Risk Level: medium — 8-K filings can contain material information, but without specific details on the content, the risk level is moderate.

Key Players & Entities

FAQ

What specific information is being disclosed under Regulation FD?

The filing does not specify the exact nature of the Regulation FD disclosure, only that it is being reported.

What financial statements and exhibits are included in this filing?

The filing indicates that financial statements and exhibits are included, but their specific content is not detailed in the provided text.

When was Alpha Cognition Inc. formerly known as Neurodyn Cognition Inc.?

The date of the name change from Neurodyn Cognition Inc. to Alpha Cognition Inc. was October 16, 2015.

What is the primary business of Alpha Cognition Inc. according to its SIC code?

Alpha Cognition Inc.'s Standard Industrial Classification (SIC) code is 2836, which corresponds to Biological Products (No Diagnostic Substances).

Where are Alpha Cognition Inc.'s principal executive offices located?

The principal executive offices of Alpha Cognition Inc. are located at 1200 - 750 West Pender Street, Vancouver, British Columbia, V6C 2T8.

Filing Stats: 586 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-07-29 16:38:47

Filing Documents

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 29, 2024 ALPHA COGNITION INC. (Exact name of registrant as specified in its charter) British Columbia 333-278997 N/A (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 1200 - 750 West Pender Street Vancouver , British Columbia V6C 2T8 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: 604 - 564-9244 (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: None Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( 240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 7.01 Regulation FD On July 29, 2024, Alpha Cognition Inc. (the Registrant") issued a press release announcing that the U.S. Food and Drug Administration (FDA) has granted approval for ZUNVEYL (benzgalantamine) previously known as ALPHA-1062, for the treatment of mild-to-moderate Alzheimer's disease. A copy of the press release is attached to this report as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information set forth in Item 7.01 and in the press release is deemed to be "furnished" and shall not be deemed "filed" for purposes of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The information set forth in Item 7.01 of this report shall not be deemed an admission as to the materiality of any information in this report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD. Item 9.01 Exhibits Exhibit Number Description 99.1* Press Release dated July 29, 2024 104 Cover Page Interactive Data File––the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. * The Exhibit relating to Item 7.01 is intended to be furnished to, not filed with, the SEC, pursuant to Regulation FD. 1 SIGNATURE Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ALPHA COGNITION INC. Date: July 29, 2024 By: /s/ Don Kalkofen Name: Don Kalkofen Title: Chief Financial Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing